Adult Dosing

Tuberculosis

• 15-30 mg/kg PO Daily x 2 months
• Alt: 50-70 mg/kg twice wkly x 2 months
• Max: 2 g/day as daily dose or 4 g/day wkly dose

Pediatric Dosing

Tuberculosis

• 15-30 mg/kg PO Daily x 2 months
• Alt: 50-70 mg/kg twice wkly x 2 months
• Max: 2 g/day as daily dose or 4 g/day wkly dose

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of active tuberculosis in combination with other antituberculous agents

• Hypersensitivity to any of the ingredients of the product
• Severe hepatic damage
• Acute gout

• N/A

Renal Dose Adjustment

• Renal impairment: dosage reduction to 12-20 mg/kg/day

Hepatic Dose Adjustment

• Severe hepatic impairment: Contraindicated

• Perform liver function test before initiating pyrazinamide therapy. Use cautiously in patients with preexisting liver disease or those at increased risk for drug related hepatitis. Discontinue the drug if signs of hepatocellular damage occurs
• Pyrazinamide inhibits renal excretion of urates, resulting into hyperuricemia. Monitor serum uric acid at baseline and periodically thereafter. Discontinue the drug if hyperuricemia accompanied by an acute gouty arthritis occurs
• Use cautiously in patients with history of diabetes mellitus, as management will be more difficult
• In cases with known or suspected drug resistance, perform in vitro susceptibility tests with recent cultures of M. tuberculosis against pyrazinamide and the usual primary drugs, as primary resistance of M. tuberculosis to pyrazinamide is not common

Cautions: Use cautiously in

• Liver diseases
• Diabetes mellitus
• Hyperuricemia

Pregnancy Category:C

Breastfeeding: Limited information indicates that pyrazinamide is excreted in breastmilk in low levels and thus would not be expected to adversely affect the breastfed infant, especially in the infant >2 months. If this drug is used during lactation monitor exclusively breastfed infants for rare cases of jaundice, hepatitis and arthralgia. The amount of rifampin in milk is insufficient to treat tuberculosis in the breastfed infant. The Centers for Disease Control and Prevention and other professional organizations state that breastfeeding should not be discouraged in women taking pyrazinamide. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). Manufacturer advises caution.

• GI: Hepatotoxicity, nausea, vomiting, anorexia
• HEMA: Thrombocytopenia, sideroblastic anemia
• ENDO: Hyperuricemia
• GU: Dysuria, interstitial nephritis
• DERM: Rashes, urticaria, pruritis, acne, photosensitivity
• MUSC: Arthralgia, myalgia
• MISC: Fever, porphyria, anemia

• Antituberculous agent; bacteriostatic or bactericidal action against susceptible strains of Mycobacterium tuberculosis
• Metabolized by liver
• Renally excreted 70%
• Half-life: 9-10 hrs

US Trade Name(s)

• Only generic available

US Availability

pyrazinamide (generic)

• TABS: 500 mg

Canadian Trade Name(s)

• Tebrazid

Canadian Availability

pyrazinamide (generic)

• TABS: 500 mg

Tebrazid

• TABS: 500 mg

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Antituberculosis Agents

Nicotinic Acid Derivatives

Infectious Disease

Antituberculosis Agents

Nicotinic Acid Derivatives

Drug Name: Pyrazinamide 500 MG Oral Tablet

Ingredient(s): Pyrazinamide

Imprint: EFF;12

Color(s): White

Shape: Round

Size (mm): 13.00

Score: 2

Inactive Ingredient(s): cellulose / colloidal silicon dioxide / croscarmellose sodium / dibasic calcium phosphate / microcrystalline

Drug Label Author:
MIKART, INC.

DEA Schedule:
Non-Scheduled